And AbbVie and Genmab scoop their ASH presentation with new data.
ApexOnco Front Page
Recent articles
The company adds royalty aggregation to its R&D business.
Zanzalintinib prevails in all comers, but full data will show if the win was driven by a subgroup.
The registrational part 2 of bezuclastinib's Summit trial reads out in July.
When your investment case breaks down, why not just do the decent thing?
A new KRAS degrader and PD-1 x Lag3 bispecific have just started phase 1.
Suzhou Zelgen’s DLL3 x DLL3 project looks better than regular T-cell engagers, with caveats.
The players are vying in the CD19 x CD20 Car-T arena.
